GlassScriptPhysician profile
Barry Fernbach
NPI 1427076736
$903.15
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $625 · 2020: $278.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $258.69 | 2019-2020 | |
| Janssen Biotech, INC. | $245.71 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $159.20 | 2019 | |
| Incyte Corporation | $125.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $62.94 | 2019 | |
| Octapharma USA, INC. | $40.39 | 2019 | |
| Amag Pharmaceuticals, INC. | $11.22 | 2020 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Fernbach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.